How a Drug Maker Profited by Slow-Walking a Promising H.I.V. Therapy; The New York Times, July 22, 2023

Gilead, a major drugmaker, has been accused of using the U.S. patent system to extend its monopolies on profitable drugs. They delayed the release of a promising H.I.V. therapy, introducing it in 2015 instead of in 2004. Lawsuits have been filed by 26,000 patients alleging that Gilead put them at risk of kidney and bone problems by exposing them to older H.I.V. drugs.

Posta un commento